116 related articles for article (PubMed ID: 2544349)
1. Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
Vokes EE; Bitran JD; Hoffman PC; Ferguson MK; Weichselbaum RR; Golomb HM
Chest; 1989 Jul; 96(1):110-3. PubMed ID: 2544349
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer.
Pujol JL; Hayot M; Rouanet P; Le Chevalier T; Michel FB
Chest; 1994 Nov; 106(5):1451-5. PubMed ID: 7956400
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with cisplatin, vindesine and mitomycin-C for advanced, inoperable non-small-cell lung cancer.
Stockler M; Raghavan D; McCaughan BC; Grygiel J; McNeil E; Gianoutsos P; Lee JH
Med J Aust; 1992 May; 156(10):698-700. PubMed ID: 1377770
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
[TBL] [Abstract][Full Text] [Related]
7. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
[TBL] [Abstract][Full Text] [Related]
8. [Cisplatin and vinca alkaloid combination chemotherapy of advanced non-small-cell lung cancer in the aged].
Teramoto S; Nagase T; Fukuchi Y; Ishida K; Yamaoka M; Matsuse T; Jo C; Orimo H
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):680-6. PubMed ID: 1964186
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
[TBL] [Abstract][Full Text] [Related]
11. [Recent changes in the management of advanced non-small cell lung cancer].
Kodama N; Kawahara M; Furuse K
Gan To Kagaku Ryoho; 1994 Nov; 21(15):2564-70. PubMed ID: 7979414
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
13. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.
Pisters KM; Kris MG; Gralla RJ; Zaman MB; Heelan RT; Martini N
J Clin Oncol; 1993 Sep; 11(9):1757-62. PubMed ID: 8394881
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens.
Hainsworth JD; Johnson DH; Hande KR; Greco FA
Am J Clin Oncol; 1989 Aug; 12(4):345-9. PubMed ID: 2547305
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
[TBL] [Abstract][Full Text] [Related]
17. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer.
Kubota K; Furuse K; Kawahara M; Kodama N; Yamamoto M; Ogawara M; Negoro S; Masuda N; Takada M; Matsui K
J Clin Oncol; 1994 Aug; 12(8):1547-52. PubMed ID: 8040666
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.
Stupp R; Mayer M; Kann R; Weder W; Zouhair A; Betticher DC; Roth AD; Stahel RA; Majno SB; Peters S; Jost L; Furrer M; Thierstein S; Schmid RA; Hsu-Schmitz SF; Mirimanoff RO; Ris HB; Pless M
Lancet Oncol; 2009 Aug; 10(8):785-93. PubMed ID: 19604722
[TBL] [Abstract][Full Text] [Related]
19. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.
Dillman RO; Herndon J; Seagren SL; Eaton WL; Green MR
J Natl Cancer Inst; 1996 Sep; 88(17):1210-5. PubMed ID: 8780630
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center.
Joss RA; Bürki K; Dalquen P; Schatzmann E; Leyvraz S; Cavalli F; Ludwig C; Siegenthaler P; Alberto P; Stahel R
Cancer; 1990 Jun; 65(11):2426-34. PubMed ID: 2159837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
